Literature DB >> 28441690

The postoperative Model for End stage Liver Disease score as a predictor of short-term outcome after transplantation of extended criteria donor livers.

Tamas Benko1, Anja Gallinat, Thomas Minor, Fuat H Saner, Georgios C Sotiropoulos, Andreas Paul, Dieter P Hoyer.   

Abstract

BACKGROUND: Recently, the postoperative Model for End stage Liver Disease score (POPMELD) was suggested as a definition of postoperative graft dysfunction and a predictor of outcome after liver transplantation (LT). AIM: The aim of the present study was to validate this concept in the context of extended criteria donor (ECD) organs. PATIENTS AND METHODS: Single-center prospectively collected data (OPAL study/01/11-12/13) of 116 ECD LTs were utilized. For each recipient, the Model for End stage Liver Disease (MELD) score was calculated for 7 postoperative days (PODs). The ability of international normalized ratio, bilirubin, aspartate aminotransferase, Donor Risk Index, a recent definition of early allograft dysfunction, and the POPMELD was compared to predict 90-day graft loss. Predictive abilities were compared by receiver operating characteristic curves, sensitivity and specificity, and positive and negative predictive values.
RESULTS: The median Donor Risk Index was 1.8. In all, 60.3% of recipients were men [median age of 54 (23-68) years]. The median POD1-7 peak-aspartate aminotransferase value was 1052 (194-17 577) U/l. The rate of early allograft dysfunction was 22.4%. The 90-day graft survival was 89.7%. Out of possible predictors of the 90-day graft loss MELD on POD5 was the best predictor of outcome (area under the curve=0.84). A MELD score of 16 or more on POD5 predicted the 90-day graft loss with a specificity of 80.8%, a sensitivity of 81.8%, and a positive and negative predictive value of 31 and 97.7%.
CONCLUSION: A MELD score of 16 or more on POD5 is an excellent predictor of outcome in ECD donor LT. Routine evaluation of POPMELD scores might support clinical decision-making and should be reported routinely in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28441690     DOI: 10.1097/MEG.0000000000000851

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  2 in total

1.  Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison.

Authors:  Georgios C Sotiropoulos; Eleftherios Spartalis; Nikolaos Machairas; Andreas Paul; Massimo Malagó; Markus Neuhäuser
Journal:  Ann Gastroenterol       Date:  2018-07-27

2.  Predicting Short-term Survival after Liver Transplantation using Machine Learning.

Authors:  Chien-Liang Liu; Ruey-Shyang Soong; Wei-Chen Lee; Guo-Wei Jiang; Yun-Chun Lin
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.